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Abstract 
Canine and human osteosarcoma (OSA) have many similarities, with the majority of reported 
cases occurring in the appendicular skeleton, gender predominance noted, high rate of me-
tastasis at the time of presentation, and a lack of known etiology for this devastating disease. 
Due to poor understanding of the molecular mechanisms underlying OSA, we have charac-
terized seven different OSA canine cell lines:  Abrams, D17, Grey, Hughes, Ingles, Jarques, and 
Marisco and compared them to U2, a human OSA cell line, for the following parameters:  
morphology, growth, contact inhibition, migrational tendencies, alkaline phosphatase staining, 
heterologous tumor growth, double-strand DNA breaks, and oxidative damage.  All results 
demonstrated the positive characteristics of the Abrams cell line for use in future studies of 
OSA.  Of particular interest, the robust growth of a subcutaneous tumor and rapid pulmonary 
metastasis of the Abrams cell line in an immunocompromised mouse shows incredible po-
tential for the future use of Abrams as a canine OSA model.  Further investigations utilizing a 
canine cell model of OSA, such as Abrams, will be invaluable to understanding the molecular 
events underlying OSA, pharmaceutical inhibition of metastasis, and eventual prevention of 
this devastating disease. 
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Introduction 
Osteosarcoma (OSA) is a deadly form of mus-
culoskeletal cancer which develops from the cells re-
sponsible for forming the bone matrix.22 In children 
and  adolescents,  OSA  is  the  most  common  type  of 
primary bone cancer,5,23 with approximately 1-3 cases 
per million annually, and 70-75% of patients being 10 
to 25 years of age.12,19 Interestingly, the incidence of 
OSA is slightly higher in males than females, with a 
ratio of 1.5:1.19,23 Factors underlying the development 
of OSA are still largely unknown, however humans 
are at a higher risk following periods of rapid ado-
lescent growth, with the metaphyseal area adjacent to 
the growth plate of long  bones  most commonly af-
fected.19,23 Most  OSA  start  as  solitary  lesions,  espe-
cially  within  the  distal  femur,  proximal  tibia,  and 
proximal  humerus.22  Although  micrometastatic  dis-
ease is likely present in approximately 80% of human 
patients, it is only detected in 8-15%,7,8 and as a result 
patients  often  die  from  pulmonary  metastatic  dis-
ease.5,22 
In canines, OSA is more common than it is in 
humans, with approximately 10,000 new cases each 
year.3 OSA is generally a disease of large breed ca-
nines  where  increasing  height  is  a  more  prominent 
risk factor then body weight.18 As in humans, males 
more commonly present  with OSA than females,5,10 Journal of Cancer 2011, 2 
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although some studies reveal no prevalence between 
sexes.1  When a dog presents with OSA, less then 10% 
of the cases have radiographic evidence of lung me-
tastasis.22 Canine OSA is most often found in the ap-
pendicular skeleton,5,8,24 originates in the metaphyseal 
region of the long bones (similar to humans), and oc-
curs  twice  as  frequently  in  the  thoracic  versus  the 
pelvic limbs.  The most common site of canine OSA is 
the  distal  radius  followed  by  the  proximal  humer-
us.5,18 Despite treatment with amputation and chem-
otherapy,  over  80%  of  dogs  succumb  to  metastatic 
disease within 2 years of diagnosis.5,24 
To  summarize,  many  commonalities  between 
human and canine OSA exist:  the long bones are most 
often  affected,  males  are  affected  more  commonly 
than females, the etiology is unknown, and very few 
cases show lung metastasis at the time of presenta-
tion.  Because of these similarities, the characteriza-
tion and use of a canine model of OSA could be in-
valuable  in  understanding  this  devastating  disease, 
aiding in assessing potential therapeutic agents and 
potentially preventing disease formation.  In this re-
port, we have characterized six canine OSA cell lines 
for  morphology,  growth,  contact  inhibition,  migra-
tional tendencies, alkaline phosphatase protein, het-
erologous tumor growth, double-strand DNA breaks, 
and oxidative damage and compared them to U2, a 
human OSA cell line. Further investigations utilizing 
a canine cell model of OSA with xenograft potential 
will be invaluable to understanding the cellular and 
molecular events underlying OSA.  
Materials and Methods 
Cell  Culture:    Canine  OSA  cell  lines  Abrams, 
D17, Grey, Hughes, Ingles, Jarques, and Marisco were 
a generous gift from Dr. Greg MacEwan, University of 
Wisconsin, Madison, Wisconsin.  The human cell line 
U2, was purchased from ATCC.  All OSA cell lines 
were  grown  in  Modified  Eagles  Medium  (MEM; 
CellgroTM)  supplemented  with  15%  fetal  bovine  se-
rum  (FBS;  HyCloneTM),  2%  MEM  vitamins,  and  1% 
each L-glutamine, non-essential amino acids, and so-
dium pyruvate.  All cells were maintained at 37º C, 
humidified with 5% CO2. 
Cell Proliferation:  Abrams, D17, Grey, Hughes, 
Ingles, Jarques, and U2 were used in this experiment.  
In order to determine the varying proliferation rates 
of the cell line(s), a seven-day proliferation trial was 
performed.  To take into account differences in cell 
size, as some OSA cells were quite large and spindloid 
in comparison to other cell lines, cells were harvested 
at the onset of this experiment when flasks reached 
90% confluency and then each cell line was diluted 
similarly before being added to the 100 mm2 plates.  
Thus, each 75 cm2 flask was trypsinized when cells 
were 90% confluent with  1 ml 0.25% trypsin-EDTA 
0.25%  for  5  min.  MEM  with  15%  FBS  (22  mL  total 
volume) was added to each flask and the cells were 
thoroughly mixed.  One mL of this suspension was 
removed and cells were counted to establish the count 
at day 0.  One mL aliquots of the remaining 21 mL 
were added to 9 mL of MEM with 15% FBS in 100 
mm2 plates.  Cell counts were performed daily (22 – 24 
h  intervals)  as  follows:  3  plates  from  each  cell  line 
were trypsinized with 0.5 mL 0.25% trypsin-EDTA for 
5 min, 3 mL MEM with 15% FBS was added, and all 3 
dishes  were combined and thoroughly  mixed. Each 
sample was diluted 1:10 with 0.4% PBS and 37% for-
maldehyde solution and counted twice.  This resulted 
in the number of cells/mL using the following calcu-
lation: [(value from counter #1) + (value from counter 
#2)] X 10 = cells/mL.  In order to standardize the cell 
count data the cell number of subsequent days was 
divided by the number of cells counted on day zero.  
Counting  was  performed  using  a  Particle  Data 
Counter  (El  Zone  180  Particle  Data,  Inc)  and  dou-
ble-checked using a hemocytometer.  The experiment 
was performed in triplicate for each cell line for 7 d.  
Growth  in  Soft  Agar:    Abrams,  D17,  Grey, 
Hughes, Ingles, and U2 were used for this experiment 
based  on  their  performance  in  the  cell  proliferation 
experiment above. Agar (GibcoTM) was reconstituted 
with 100 mL MEM with 15% FBS to 0.3% and 0.8% 
final concentration, boiled for 1 min and autoclaved.  
The agar was cooled slightly, then 100 mL of agar was 
mixed with 2.5 x 105 cells in 5 mL MEM with 15% FBS. 
Each cell-agar mixture (5 mL) was added to a 100 mm2 
dish.  Each experiment was performed in duplicate.  
The  plates  were  visualized  at  4x  daily  and  colony 
measurements were taken and photographed on 4X 
power at 8d, 10d, 11d, 15d, 18d and 22d post-plating. 
Images were acquired using a Zeiss Axiovert 200M 
microscope equipped with a 63X 1.4 N/A oil immer-
sion  objective  and  Hammatsu  ORCA-ER  cooled 
charge-coupled device camera.  
Boyden Chamber Assay:  Abrams and U2 were 
assessed in this experiment due to the strong perfor-
mance of Abrams in the cell proliferation and colony 
growth experiments.  Ingles was also used as a poor 
growth  control  cell  line  (data  not  shown).  The  cell 
lines were grown to 80% confluency and FBS starved 
for 24 h prior to harvesting.  Cultures were harvested 
and volume adjusted to yield  2.5 x 106 cells/mL. Cells 
suspended in either serum-free growth medium (300 
μL)  or  normal  growth  medium  (300  μL)  with  were 
added  to  the  appropriate  wells  (fibronectin-  or 
BSA-coated)  of  the  Boyden  chambers  under  sterile 
conditions,  as  per  manufacturers  instructions.    The Journal of Cancer 2011, 2 
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cells were incubated for 24 h and 6 drops of Cell Stain 
Solution  were  added  to  each  well  after  removal  of 
media.    The  fibronectin-coated  Boyden  chambers 
from the test plate were carefully removed and the 
cells were removed from inside the chamber.  Boyden 
chambers were then placed in the test plate wells with 
stain (from above).  The same procedure was followed 
for the BSA-coated control chambers and they were 
placed  in  the  control  wells  with  stain.    Plates  were 
then incubated at room temp for 30 min. Cell stain 
was removed and the wells were washed with PBS. 
Extraction  buffer  (300  µL)  was  added  to  the  empty 
wells in the test and control plates.  Boyden chambers 
were washed thoroughly with distilled water, cleaned 
and placed into extraction buffer in their respective 
plates.  Plates were gently shaken to elute stain for 10 
min, and then 100 µL of stained solution was trans-
ferred from the elution wells into a microtiter plate.  
Absorbance at 540 nm was analyzed.   
Heterologous  Tumor  Growth  and  Metastasis:  
Abrams,  Ingles,  and  U2  were  used  for  this  experi-
ment. Rag1 male mice were purchased from the Jack-
son  Laboratory,  and  acclimated  in  Colorado  State 
University’s central animal care facility, which is fully 
accredited by the American Association for Accredi-
tation  for  Laboratory  Animal  Care.  All  animal  pro-
cedures  were  conducted  following  an  Animal  Care 
and Use Research Protocol approved by the Colorado 
State  University  Animal  Care  and  Use  Committee. 
Mice were allowed ad libitum access to food and water 
throughout the duration of experimentation. 8 wk old 
mice were injected subcutaneously mid-dorsally with 
1 x 106 cells suspended in 0.2 mL PBS, and monitored 
daily  for  tumor  growth.  At  10  wk  post-injection,  a 
MRI  was  performed  on  each  mouse  to  determine 
possible lung metastasis.  Mice were then euthanized, 
necropsied, and tissues submitted for histopathologic 
examination. 
Alkaline Phosphatase Staining:  Abrams, D17, 
Grey, Hughes, Ingles, Jarques, and U2 were evaluated 
for expression of alkaline phosphatase and fibroblasts 
were used as negative controls.  Chamber slides were 
fixed  for  10  min  in  1%  paraformaldehyde  and 
air-dried.   Slides were rehydrated in buffer (100mM 
Tris-HCl, 100mM NaCl and 50mM MgCl2), washed in 
TBS with 0.05% TBS (TBS-T0.5) and coated with DI 
water to keep moist.  For staining, 100μl BCIP/NBT, 
prepared  as  instructed  in  kit  (Vector  Laboratories, 
SK-5400) was added to each reservoir without intro-
ducing bubbles and slides were allowed to sit covered 
and in the dark for 1 h.  The slides were rinsed with 
TBS-T0.5 and another 100 μl BCIP/NBT was added to 
each reservoir. The slides were incubated overnight 
and 100 μl BCIP/NBT was added to each reservoir, 
allowed to sit for 1 h and rinsed with TBS-T0.5.  The 
slides were then counterstained with hematoxylin for 
30 s and coverslipped with Kaiser’s aqueous mount-
ing media. 
Phosphorylated  H2AX  Immunocytochemistry: 
Cells were cultured for 24 h on plastic chamber slides 
and then washed with PBS followed by fixation with 
4%  paraformaldehyde  for  15  minutes.  Following  a 
second wash with PBS, cells were then permeabilized 
with  0.2%  Triton  X  with  PBS  for  10  minutes.  Cells 
were then covered with parafilm and incubated with 
10% goat serum with PBS overnight at 4ºC. Following 
overnight incubation, the cells were then covered with 
parafilm  and  incubated  with  a  mouse  monoclonal 
phosphorylated histone H2AX (Ser139) (Millipore) in 
10% goat serum with PBS for 1 hour at 37°C. The cells 
were then washed three times for 10 minutes each in 
PBS, followed by a 1-hour incubation at 37°C with the 
appropriate secondary antibody. The slides were then 
washed three times for 10 minutes each in PBS, and 
then counter stained with Vectashield mounting me-
dia with DAPI. The cells were cover slipped and vis-
ualized with Olympus AX70 equipped with a cooled 
CCD Sensys camera. MacProbe was utilized to obtain 
images.  
Oxidative Damage: Cells were cultured for 24 h 
on plastic chamber slides and then washed with PBS 
followed by fixation with 4% paraformaldehyde for 
15 minutes. Following a second wash with PBS, cells 
were then permeabilized with 0.2% Triton X with PBS 
for 10 minutes. Cells were then covered with parafilm 
and incubated with 10% goat serum with PBS over-
night at 4ºC. Following overnight incubation, the cells 
were then covered with parafilm and incubated with 
a  FITC-8-oxoguanine  protein  conjugate  (Kamiya  Bi-
omedical Company) in 10% goat serum with PBS for 1 
hour at 37°C. The cells were then washed three times 
for 10 minutes each in PBS and counter stained with 
Vectashield mounting media with DAPI. The cell is 
cover  slipped  and  visualized  with  Olympus  AX70 
equipped  with  a  cooled  CCD  Sensys  camera.  Mac-
Probe was utilized to obtain images.  
Statistical  Methods:  Analysis  of  variance  was 
used  to  determine  statistical  significance  with 
GraphPad  Prism  software.  When  statistical  differ-
ences were detected, Tukey’s post hoc test was used to 
determine individual variations.  As the U2 cell line is 
currently employed most commonly and the purpose 
of these experiments is identifying whether a compa-
rable canine cell line exists, all means were compared 
to U2. 
Results 
During  the  7-day  testing  period,  the  cell  lines Journal of Cancer 2011, 2 
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were vastly different in their proliferation character-
istics  (Fig.  1).  Overall  cellular  proliferation  demon-
strates that at day 7 the Abrams line was an aggres-
sively growing OSA cell line, as it neither died off nor 
reached  a  plateau.    Additionally,  the  Abrams  line 
quickly  grew  colonies  in  soft  agar,  an  indicator  of 
anchorage-independent growth, and produced one of 
the highest colony diameters, 2768.9 μm over the 22 
day testing period (data not shown).  In comparison, 
maximal diameters for the other cells  lines were as 
follows:  2339.3 μm for D17, 1301.6 μm for U2, and 
529.3  μm  for  Ingles.    Ingles  in  addition  to  having 
minimal soft agar colony growth over the 22 day pe-
riod was also one of the slower proliferators, to the 
point where the data needed to be represented on a 
different Y-axis in order to be visualized (Fig 1).  The 
cell lines Grey and Hughes were suicidal early in the 
cell proliferation assay, dying by day 4 in the assay 
(data not shown), and had the smallest colony growth 
in soft agar after 22 days (529 μm maximal diameter 
for both of these lines).   Additionally, Jarques also 
grew  poorly  in  the  proliferation  assay  (data  not 
shown as it was lower than Ingles), was difficult to 
maintain in culture and did not grow in the soft agar.  
Thus, as we were looking for a cell line that would 
model canine osteosarcoma over usage of the human 
U2 cell line, Grey, Hughes and Jarques were not car-
ried  further  in  the  Boyden  Chamber  assay  nor  the 
xenografting experiment. 
The migrational capacity of cells is indicative of 
metastatic  potential.  Boyden  chamber  wells  were 
coated with FN to assess migration or BSA as a nega-
tive control. Abrams demonstrated significant migra-
tional tendencies compared to the BSA negative con-
trols (Fig. 2) and performed significantly better than 
U2  in  this  assay.    Ingles,  as  the  negative  or  poor 
growth control demonstrated no migrational tenden-
cies (data not shown).  Furthermore, the Abrams cells 
consistently stained positive for alkaline phosphatase 
(Fig. 3-4) with all other cell lines having a poor and 
inconsistent staining pattern.  Based upon these re-
sults, Abrams was selected as an aggressive OSA line 
comparable to U2. 
 
 
Figure 1.  OSA cell lines proliferate differently over time, with the Abrams cell line outperforming U2.  Cell 
numbers per cell line (U2, Abrams, D17 and Ingles represented) over the 7 day experimental period.  Please note that the 
cell numbers (on the Y axis) spans 0-200,000 cells for all cell lines except the Ingles which proliferated so slowly that the 
Y-axis spans 0-1,000 in order to visualize the data for this cell line.  Error bars represent standard deviation.   Journal of Cancer 2011, 2 
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Figure 2.  Abrams cells migrate more extensively 
than U2 cells in the Boyden chamber.  Chamber wells 
were coated with fironectin (Black Bars) or bovine serum 
albumin (Checkered Bars), and 750,000 cells were added to 
each well.  After 24h cells were stained, lysed, and optical 
density at 540 nm was read. Statistical differences were 
determined via two-way analysis of variance, with cell type 
(p=0.003) and coating (p<0.001) being significant, as well as 
the cell type and coating interaction (p=0.0086). 
 
Subcutaneous injection of Abrams cells resulted 
in tumor growth in the skin with lung metastases 10 
wks post-injection (Fig. 3).  These tumors were grossly 
evident in the skin and could be identified grossly as 
suspicious  areas  within  the  lung  tissue  and  histo-
pathologically in both the skin and lung.  However, 
use of MRI at 10 weeks was not sensitive enough to 
declare metastasis and  only after going back  to the 
images after gross and histological examination could 
the areas be characterized as suspicious on MRI scan. 
Other  internal  organs  were  examined  grossly  and 
histopathologically and did not contain evidence of 
metastases.  Subcutaneous injections of Ingles or U2 
cells did not result in tumor growth in the skin nor 
metastasis to lungs or other organs.   
γH2AX  immunocytochemistry  demonstrated 
that the biologically more aggressive canine and hu-
man  OSA  cell  lines  (Abrams,  D17,  Grey,  Hughes, 
Marisco, and U2) demonstrated more nuclear foci of 
phosphorylated γH2AX as compared to the less ag-
gressive  canine  OSA  cell  lines  (Ingles  and  Jarques) 
(Fig. 4). 
Additionally,  the  biologically  more  aggressive 
canine  OSA  cell  lines  (Abrams,  D17,  Grey,  and 
Marisco) demonstrate increased oxidative damage as 
evidenced  by  increased  mitochondrial  and  nuclear 
staining  of  8-oxoguanine.  The  canine  OSA  cell  line 
Hughes demonstrates intermediate staining, while the 
less  aggressive  canine  OSA  cell  lines  (Ingles  and 
Jarques) and the human OSA cell line (U2) demon-
strate minimal staining (Fig. 5). 
 
Figure  3.    The  Abrams 
OSA  cell  line  produces 
an  aggressive  tumor  in 
the Rag1 mouse.  1. Het-
erologous tumor growth of 
Abrams cells in Rag1 mouse.  
Grossly, the tumor measures 
13.4 mm long x 8.8 mm wide 
10  wk  post  injection.    2. 
Histopathology  of  heterol-
ogous Abrams skin tumor 10 
wk  post  xenografting  via 
subcutaneous  injection 
(Hematoxylin  and  Eosin).  
Arrow  denotes  a  mitotic 
figure.    3.  Heterologous 
Abrams cell tumor metasta-
sis to lung (Hematoxylin and 
Eosin).  Inset of lung metas-
tasis  at  higher  power.    4. 
Abrams cells stain positively 
for alkaline phosphatase with 
hematoxylin counterstain. 
 Journal of Cancer 2011, 2 
 
http://www.jcancer.org 
267 
 
Figure 4. The biologically more-aggressive OSA cell 
lines  demonstrate  increased  double-strand  DNA 
damage. In all cell types nuclear phosphorylated H2AX 
foci are stained red with DAPI counterstain. γH2AX im-
munocytochemistry demonstrates that Abrams, D17, Grey, 
Hughes, and U2 exhibit more nuclear foci of phosphory-
lated γH2AX as compared to intermediate staining within 
Marisco and the less aggressive canine OSA cell lines (Ingles 
and Jarques).  U2 cells have the highest level of nuclear 
HSAX staining compared to all other cell lines.  Repre-
sentative images from the following osteosarcoma cell lines 
are within the panels indicated:  A) Abrams, B) D17, C) 
Grey, D) Hughes, E) Ingles, F) Jarques, G) Marisco, H) U2. 
 
Figure 5. The biologically more-aggressive OSA cell 
lines  demonstrate  increased  mitochondrial  and 
nuclear  oxidative  evidence  characterized  by  in-
creased  DNA  8-oxoguanine.  In  all  cell  types  mito-
chondrial and nuclear 8-oxoguanine foci are stained green 
with DAPI for nuclear counterstain.  Abrams, D17, Grey, 
and Marisco demonstrate increased oxidative damage as 
evidenced by increased mitochondrial and nuclear staining 
of  8-oxoguanine.    Hughes  demonstrates  intermediate 
staining,  while  the  less  aggressive  canine  OSA  cell  lines 
(Ingles  and  Jarques)  and  the  human  OSA  cell  line  (U2) 
demonstrate  minimal  staining  of  8-oxoguanine.    Repre-
sentative images from the following osteosarcoma cell lines 
are within the panels indicated:  A) Abrams, B) D17, C) 
Grey, D) Hughes, E) Ingles, F) Jarque, G) Marisco, H) U2. 
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Discussion 
Although  many  common  characteristics  exist 
between human and canine OSA, the underlying eti-
ology  of  the  disease  is  poorly  understood  in  either 
species.  Initial genetic characterization of a few hu-
man and canine OSA cell lines have indicated muta-
tions  in  PTEN16,  inactivation  of  p5315  and  overex-
pression  of  met  and  sis  oncogenes6,17  to  be  of  im-
portance in these tumors.  Further characterization of 
canine OSA cell lines will provide information with 
which to select an appropriate in vitro model to aid in 
identifying  molecular  and/or  genetic  mechanisms 
underlying this devastating tumor, as well as provide 
an experimental platform to test potential therapeutic 
interventions. Based upon our results, the canine os-
teosarcoma Abrams cell line could indeed be utilized 
as  such,  as  these  cells  possess  more  characteristics 
indicative of metastatic OSA compared to the human 
cell line currently employed, U2. 
Of all lines tested, Abrams continued its rapid 
proliferation without dying off, indicative of an ag-
gressive and continuously growing phenotype. Fur-
ther, the Abrams cells showed significant differences 
in migration potential. Additionally, the Abrams cell 
line produced large colonies in soft agar, indicating 
capability  of  anchorage-independent  growth  with 
little  contact  inhibition,  indicative  of  carcinogenesis 
and metastatic potential. Only the Abrams cells con-
sistently stained positively for alkaline phosphatase, 
an enzyme used to differentiate OSA from other soft 
tissue tumors on histopathology, and one that is often 
used  to  correlate  with  prognosis  in  OSA  pa-
tients.7,11,20,21  In some studies, elevated serum levels of 
alkaline  phosphatase  are  correlated  with  approxi-
mately  50%  shorter  survival  times  despite  assertive 
treatment.7,11,19 
Previous  experiments  correlate  significant  cell 
migration in a Boyden chamber with increased inva-
sive  properties  in vivo.4  The  Abrams  cells  migrated 
extensively, demonstrating a high potential to be in-
vasive in vivo, surpassing even the migrational capac-
ity of the human U2 line.  Following  subcutaneous 
injection  into  Rag1  mice,  only  the  Abrams  cell  line 
formed subcutaneous tumors at the site of injection 
and  metastasized  to  lung  tissue.    Fitzpatrick  et  al. 
demonstrated that the D17 cell line could be utilized 
as a xenograft, but there was no indication of metas-
tasis (9).  Moreover, Kanaya et al. utilized the POS cell 
line in their studies of the anti-tumor effect of adeno-
viral-vector mediated p53 gene transfers in nude mice 
but there again was no indication of metastasis after 
POS xenograft formation in these mice.13  As tumor 
development and subsequent formation of metastases 
are hallmark characteristics of OSA, the Abrams cell 
line proved to be a good choice for a model of OSA 
metastasis. Osteoid was not easily detectable in his-
topathologic sections of the skin or lung tumor sites, 
though it is considered to be a histological indicator of 
OSA.    However,  minimal  or  non-detectable  osteoid 
may  be  secreted  in  poorly  to  undifferentiated  OSA 
and thus not be identified on routine histological sec-
tion.  Moreover, additional characteristics of neoplasia 
were  noted  including  open  nuclei,  frequent  mitotic 
figures, anisokaryosis, and anisocytosis (Fig. 3).   
Carcinogenesis  in  general  is  associated  with 
DNA  replication  stress  and  oxidative  damage,  re-
sulting in DNA double-strand breaks, genomic insta-
bility, and selective pressure for p53 mutations. DNA 
double strand breaks result in massive relaxation of 
chromatin coiling.14 Misrepaired or unrepaired DNA 
double  strand  breaks  contributes  to  chromosomal 
aberrations leading to cell death, mutation, and on-
cogenic transformation.14 H2AX is a member of the 
histone H2A family and is involved in nucleosomal 
organization  of  chromatin.2  The  basic  subunit  of 
chromatin, the nucleosome, consists of a core of eight 
proteins, two from each of the H2A, H2B, H3, and H4 
families, with about 140 bp of DNA coiled around the 
core  and  the  fifth  histone  family,  H1,  on  the  linker 
DNA  acting  as  a  bridge  between  adjacent  nucleo-
somes.2  Each  nucleosome  contains  two  H2A  mole-
cules  and  H2AX  is  synthesized  in  a  replica-
tion-dependent  and  replication-independent  man-
ner.2 Upon double-strand break formation, members 
of the PI3K-like kinase family, including ataxia telan-
giectasia  mutated  (ATM),  ataxia  telangiectasia  and 
Rad3-related  (ATR),  and  DNA-dependent  protein 
kinase  (DNA-PK),  are  activated  and  phosphorylate 
H2AX  and  other  DNA  repair  and  checkpoint  pro-
teins.2  As  double-strand  DNA  breaks  are  repaired, 
γH2AX  foci  disappear.2  There  are  two  potential 
mechanisms  of  γH2AX  removal:  dephosphorylation 
of γH2AX or removal of phosphorylated γH2AX from 
the chromatin.2 Dephosphorylation depends upon the 
phosphatases PP2A and PP4C. Phosphorylation of the 
H2AX histone variant on a serine four residues from 
the  carboxyl  terminus  is  a  very  sensitive  assay  for 
double strand break measurements.2,14 Thirty minutes 
following a DNA double strand break, large numbers 
of  γH2AX  molecules  form  in  the  chromatin  around 
the  break  site,  creating  a  focus  where  proteins  in-
volved in DNA and chromatin remodeling accumu-
late.2 The Abrams cell lines demonstrate high levels of 
both double-strand DNA breaks and oxidative dam-
age, further supporting its use as an aggressive canine 
OSA cell line.  Journal of Cancer 2011, 2 
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The growth of cancers is accompanied by pro-
gressive infiltration, invasion, and destruction of the 
surrounding tissues.  Given how quickly the Abrams 
cell  line  proliferated,  its  ability  to  migrate  in  the 
Boyden  chamber  experiment,  positive  staining  for 
alkaline  phosphatase,  increased  numbers  of  dou-
ble-strand DNA breaks, increased mitochondrial and 
nuclear oxidative damage, and lack of contact inhibi-
tion in soft agar, the Abrams line is an excellent OSA 
canine model, particularly metastatic OSA.  Because 
this cancer is so devastating in the canine, further ex-
perimentations  to  develop  therapeutic  interventions 
would benefit veterinary medicine. Furthermore, with 
the myriad of similarities between species, it would be 
beneficial to have a working canine OSA model that 
could be used to further the advancement of a human 
cure.  A comprehensive protein comparison between 
canine and human OSA would allow commonalities 
to be known and studies undertaken to alter the ex-
pression of specific proteins with the goal of tumor 
suppression.    Evaluation  of  double-strand  DNA 
breaks in spontaneously occurring canine OSA cases 
may provide additional clinically relevant prognostic 
information.  Given  how  rapidly  OSA  metastasizes, 
and that metastatic spread greatly reduces the possi-
bility  of  remission  of  the  disease,  no  achievement 
would confer greater benefit on patients then methods 
to  prevent  the  disease  and/or  prevent  its  distant 
spread.  Currently, the inhibition of OSA metastasis, 
as well as the suppression of tumor growth, is still one 
of  the  most  urgent  issues  in  orthopedic  oncology.  
Identification of canine transplantable OSA cell lines 
such as Abrams, are potentially useful to clarify fac-
tors that are involved in cell-to-matrix interactions as 
well  as  for  analysis  of  the  aggressive  behavior  and 
metastatic potential. 
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